Med BioGene Inc.

Med BioGene Inc.

July 16, 2009 08:30 ET

Med BioGene and the University of Ottawa Heart Institute Publish Study Demonstrating Potential New Diagnostic and Therapeutic Gene Expression Markers for Coronary Artery Disease

VANCOUVER, BRITISH COLUMBIA--(Marketwire - July 16, 2009) - Med BioGene Inc. (TSX VENTURE:MBI) today announced the publication on July 10, 2009 online ahead of print in Arteriosclerosis, Thrombosis, and Vascular Biology - a peer-reviewed journal of the American Heart Association - of a study demonstrating potential new diagnostic and therapeutic gene expression markers for coronary artery disease. See

The study, entitled "Functional analysis of the chromosome 9p21.3 coronary artery disease risk locus", was conducted in collaboration with a team of internationally acclaimed researchers and physicians at the University of Ottawa Heart Institute ("UOHI"). The UOHI team was led by Dr. Ruth McPherson, Director of the Atherogenomics Laboratory at UOHI and Professor of Medicine and Biochemistry at the University of Ottawa. The MBI team was led by Drs. Bradley W. McLean and Christine Buerki and included Dr. Richard C. Cook, Clinical Assistant Professor of Cardiovascular Surgery at the University of British Columbia.

The research was based on a previous study by UOHI published in the journal Science detailing the association of DNA sequence variations, known as single nucleotide polymorphisms (SNPs), in the 9p21.3 locus with an increased risk for coronary artery disease.

The new publication demonstrates the relationship between the 9p21.3 risk locus, the gene expression of the recently identified ANRIL transcript and the activation of atherosclerosis related pathways using gene expression analysis of blood samples obtained from healthy and diseased patients. These pathways represent potential new targets for diagnosis, risk assessment and therapeutic intervention of coronary artery disease.

About Med BioGene

MBI is a life science company focused on the development and commercialization of genomic-based personalized clinical laboratory diagnostic tests.

MBI's lead product, LungExpress Dx™, is expected to be the first commercially available gene expression-based test for early-stage non-small-cell lung cancer that analyzes the molecular profile of a patient's tumour to provide information to assist in tailoring treatment for that specific patient. LungExpress Dx™ is the first and only gene expression-based test for non-small-cell lung cancer shown to assist in determining a patient's benefit from chemotherapy and prognosis for survival.

MBI is committed to advancing personalized medicine by commercializing tests that provide clinically relevant information to both save lives and reduce health care costs.

Certain statements in this press release contain forward-looking information under applicable Canadian securities legislation. Words such as "anticipates", "believes", "estimates", "expects", "intends", "may", "plans", "projects", "will", "would" and similar expressions are intended to identify forward-looking information, although not all forward-looking information contains these identifying words. Forward looking information includes, but is not limited to, that with respect to future profits, future product revenues, future operations and plans, the use of proceeds from financings, the timing of clinical trials and the completion date for clinical trials and the prospects for negotiating partnerships or collaborations and their timing. This forward-looking information is only a prediction based upon MBI's current expectations, and actual events or results may differ materially. MBI may not actually achieve the plans, intentions or expectations disclosed in its forward-looking information. Forward-looking information is subject to known and unknown risks and uncertainties and is based on uncertain assumptions that could cause MBI's actual results and the timing of events to differ materially from those anticipated in such forward-looking information. You are cautioned not to place undue reliance on this forward-looking information, which speaks only as of the date of this press release. MBI's forward-looking information does not reflect the potential impact of any future partnerships, collaborations, acquisitions, mergers, dispositions, joint ventures or investments that MBI may make. All forward-looking information is qualified in its entirety by this cautionary statement and MBI undertakes no obligation to revise or update any forward-looking information as a result of new information, future events or otherwise after the date of this press release, other than as required by applicable law.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information